Skip to main content

Clinical Cardiology

RSS  

Articles

  • Cilostazol or Double-dose Clopidogrel in "Clopidogrel Resistance"?

    Dual anti-platelet therapy with aspirin and clopidogrel reduces cardiac events in patients who have acute coronary syndromes (ACS) and in patients who have percutaneous coronary intervention (PCI). Recently, the phenomenon of "clopidogrel resistance" has received much attention because of the clinical problems of stent thrombosis and recurrent ACS. However, a precise definition of this clinical entity is lacking.
  • ICD Complications

    This report from the implantable cardioverter defibrillator (ICD) portion of the National Cardiovascular Data Registry focuses on the relationships of gender to in-hospital, ICD-associated adverse events.
  • Clinical Briefs in Primary Care Supplement

  • Pharmacology Watch

    Aspirin dose and cardioprotection; uncovering modafinil's abuse potential; proton-pump inhibitors and clopidogrel; FDA actions.
  • Sudden Death in Athletes

    The U.S. National Registry of Sudden Death in Athletes assembles and analyzes data on the deaths of young athletes who participate in competitive sports.
  • Endothelial Function and Atherosclerosis

    Many reports evaluating coronary risk factors in overtly healthy individuals have been highlighted in a variety of preventative cardiology programs, guidelines, and sources. The Framingham Study gave an amazingly powerful kick start to the recognition of coronary risk factors.
  • Clopidogrel Plus Proton-Pump Inhibitors

    Since the risk of gastrointestinal bleeding is increased when clopidogrel is added to aspirin therapy in patients with acute coronary syndromes (ACS), many prescribe proton-pump inhibitors (PPIs) to reduce this risk. However, mechanistic studies suggest that PPIs may reduce the effectiveness of clopidogrel.
  • PCI vs. CABG for Severe CAD: The SYNTAX Study

    Revascularization, in conjunction with optimal medical therapy, remains a critical component in therapy for patients with obstructive coronary artery disease (CAD).
  • Physician Experience vs. Hospital Volume in Primary PCI

    Efforts to decrease door-to-balloon time for primary percutaneous intervention (PCI) in an acute ST elevation myocardial infarction (STEMI), may include preferential triage to hospitals expert in primary PCI, partly because of evidence suggesting better outcomes.
  • Management of Asymptomatic Severe Mitral Regurgitation

    The optimal timing of surgery for asymptomatic severe mitral valve regurgitation (MR) is unclear. Thus, Kang et al from South Korea studied the outcomes of patients treated with early surgery to those treated more conservatively in a prospective observational study.